The future of telehealth in type 1 diabetes.
Curr Opin Endocrinol Diabetes Obes
; 29(4): 397-402, 2022 08 01.
Article
in English
| MEDLINE | ID: covidwho-1922400
ABSTRACT
PURPOSE OF REVIEW Although telemedicine and telehealth services have been a part of type 1 diabetes (T1D) clinical care for several decades, the expansion of in-home telemedicine during the COVID-19 pandemic significantly increased interest in long-term use as part of routine care. This review highlights the current literature regarding telemedicine in T1D care as well as the benefits and barriers to use in a postpandemic world. RECENT FINDINGS:
Telemedicine has increased patient contact with healthcare providers, allowing for more frequent insulin dose adjustments and improvements in glycemic outcomes. In addition to routine clinical care, T1D device training and mental healthcare have been successful through telemedicine. Significant barriers to continued telemedicine care exist, including patient access and technology knowledge, language, and loss of face-to-face interaction. Healthcare providers additionally face unpredictable reimbursement and loss of continuity across state lines, and lack of resources and training for device downloads and telemedicine software.SUMMARY:
Telemedicine can be successfully used in T1D care and has the potential to significantly impact glycemic and long-term outcomes. Due to continued interest for in-person visits by people with T1D and providers, it is likely that long-term telemedicine use will include a hybrid format.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Telemedicine
/
Diabetes Mellitus, Type 1
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Curr Opin Endocrinol Diabetes Obes
Journal subject:
Endocrinology
/
Metabolism
Year:
2022
Document Type:
Article
Affiliation country:
Med.0000000000000745
Similar
MEDLINE
...
LILACS
LIS